Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avidity Biosciences Inc (NQ: RNA )

44.48 -1.17 (-2.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,998,431
Open 45.85
Bid (Size) 44.00 (6)
Ask (Size) 44.48 (1)
Prev. Close 45.65
Today's Range 44.05 - 46.09
52wk Range 4.825 - 48.80
Shares Outstanding 54,462,518
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unveiling 7 Analyst Insights On Avidity Biosciences
Via Benzinga
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... 
Via Benzinga

Performance

YTD
+385.59%
+385.59%
1 Month
-0.87%
-0.87%
3 Month
+18.27%
+18.27%
6 Month
+84.56%
+84.56%
1 Year
+530.03%
+530.03%

More News

Read More
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Via MarketBeat
The Analyst Landscape: 7 Takes On Avidity Biosciences
Via Benzinga
RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
(RNA) - Analyzing Avidity Biosciences's Short Interest
Via Benzinga
Chart Of The Day: Avidity Biosciences - Something's Up?
Via Talk Markets
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
Via Investor's Business Daily
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
Via InvestorPlace
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
Via The Motley Fool
Topics Economy
Exposures Interest Rates
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Via Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
Via Benzinga
Topics ETFs
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
Via Benzinga
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Crude Oil Moves Higher; Vera Bradley Shares Slide
Via Benzinga
Exposures Fossil Fuels
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Jumps 300 Points; Oracle Shares Spike Higher
Via Benzinga
Why Avidity Biosciences Shares Are Trading Higher Wednesday
Via Benzinga
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A High Point
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.